Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial

The Lancet. Gastroenterology & Hepatology
James O LindsayEuropean Crohn's and Colitis Organisation

Abstract

The randomised controlled ASTIC trial showed no benefit of mobilisation and autologous haematopoietic stem-cell transplantation (HSCT) compared with mobilisation followed by conventional therapy using a stringent primary endpoint (steroid-free clinical remission for 3 months with no endoscopic or radiological evidence of intestinal inflammation) in patients with treatment-refractory Crohn's disease. We now assess HSCT in patients enrolled in the ASTIC trial using endpoints that are traditional for clinical trials in Crohn's disease, and identify factors that predict benefit or harm. Patients who underwent mobilisation and were randomly assigned to conventional therapy in the ASTIC trial were offered HSCT at 1 year and underwent complete assessment for a further year. We report analyses of the combined cohort of patients who underwent HSCT at any time during the ASTIC trial programme. The primary outcome for this analysis was 3-month steroid-free clinical remission at 1 year after HSCT (Crohn's Disease Activity Index [CDAI] <150). We also examined the degree of endoscopic healing at 1 year. Multivariate analysis was performed to identify factors associated with achieving the primary endpoint by using logistic regression, and fac...Continue Reading

Citations

Jan 13, 2018·Journal of Crohn's & Colitis·John A SnowdenUNKNOWN Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and EBMT (JACIE)
Aug 4, 2018·Clinical Medicine : Journal of the Royal College of Physicians of London·John A SnowdenJames O Lindsay
Oct 28, 2018·Nature Reviews. Urology·Uros MilenkovicFabio Castiglione
Apr 7, 2019·Bone Marrow Transplantation·Rafael F DuarteUNKNOWN European Society for Blood and Marrow Transplantation (EBMT)
May 22, 2019·World Journal of Stem Cells·Györgyi Műzes, Ferenc Sipos
Feb 23, 2020·Therapeutic Advances in Chronic Disease·Karl Hazel, Anthony O'Connor
Oct 19, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Andrea CassinottiSergio Segato
Oct 28, 2020·Annual Review of Medicine·Tobias AlexanderJohn A Snowden
Feb 6, 2021·International Journal of Molecular Sciences·Sara CasatiAnna T Brini
Dec 5, 2020·Analytical Cellular Pathology (Amsterdam)·Carl Randall HarrellVladislav Volarevic
Jan 12, 2021·Journal of Immunology Research·B SensiA Divizia
Nov 13, 2020·World Journal of Stem Cells·Milton Artur RuizRichard K Burt
Nov 13, 2020·World Journal of Stem Cells·Rangnath MishraAmar B Singh
May 5, 2020·Current Drug Targets·Agata BiniendaMaciej Salaga
Jul 27, 2021·Frontiers in Immunology·Ida PastorePaolo Fiorina
Jul 12, 2021·The Journal of Allergy and Clinical Immunology. in Practice·Shintaro OnoHirokazu Kanegane
Oct 12, 2019·Hematology, Transfusion and Cell Therapy·Milton Artur RuizLuiz Gustavo de Quadros
Jun 24, 2021·Journal of Crohn's & Colitis·Tim RaineGarret Cullen
Sep 29, 2019·Inflammatory Intestinal Diseases·Philipp SchreinerGerhard Rogler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.